quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:43·625d
PRRelease
TFF Pharmaceuticals Inc. logo

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFFP· TFF Pharmaceuticals Inc.
Health Care
Original source

Companies

  • TFFP
    TFF Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • May 19UpdateH.C. Wainwright$22.00

Related

  • PR441d
    TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration
  • SEC486d
    SEC Form DEF 14A filed by TFF Pharmaceuticals Inc.
  • SEC498d
    SEC Form PRE 14A filed by TFF Pharmaceuticals Inc.
  • SEC499d
    TFF Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • SEC519d
    SEC Form 10-Q filed by TFF Pharmaceuticals Inc.
  • 13D/G520d
    Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.
  • SEC525d
    SEC Form NT 10-Q filed by TFF Pharmaceuticals Inc.
  • SEC525d
    TFF Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022